Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A selective phenelzine analogue inhibitor of histone demethylase LSD1.

Prusevich P, Kalin JH, Ming SA, Basso M, Givens J, Li X, Hu J, Taylor MS, Cieniewicz AM, Hsiao PY, Huang R, Roberson H, Adejola N, Avery LB, Casero RA Jr, Taverna SD, Qian J, Tackett AJ, Ratan RR, McDonald OG, Feinberg AP, Cole PA.

ACS Chem Biol. 2014 Jun 20;9(6):1284-93. doi: 10.1021/cb500018s. Epub 2014 Apr 7.

2.

Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.

Culhane JC, Wang D, Yen PM, Cole PA.

J Am Chem Soc. 2010 Mar 10;132(9):3164-76. doi: 10.1021/ja909996p.

3.

Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2).

Mino K, Nishimura S, Ninomiya S, Tujii H, Matsumori Y, Tsuchida M, Hosoi M, Koseki K, Wada S, Hasegawa M, Sasaki R, Murakami-Yamaguchi Y, Narita H, Suzuki T, Miyata N, Mizukami T.

Biosci Biotechnol Biochem. 2014;78(6):1010-7. doi: 10.1080/09168451.2014.910104. Epub 2014 Jun 13.

PMID:
25036127
4.

The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.

Murray-Stewart T, Woster PM, Casero RA Jr.

Amino Acids. 2014 Mar;46(3):585-94. doi: 10.1007/s00726-013-1485-1. Epub 2013 Mar 19.

5.

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.

Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, Liu W, Dong S, Redell M, Mo Q, Song Y.

J Hematol Oncol. 2016 Mar 12;9:24. doi: 10.1186/s13045-016-0252-7.

6.

Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.

Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J.

Neuro Oncol. 2011 Aug;13(8):894-903. doi: 10.1093/neuonc/nor049. Epub 2011 Jun 8.

7.

Human histone demethylase LSD1 reads the histone code.

Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A.

J Biol Chem. 2005 Dec 16;280(50):41360-5. Epub 2005 Oct 13.

8.
9.

Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.

El Mansouri FE, Nebbaki SS, Kapoor M, Afif H, Martel-Pelletier J, Pelletier JP, Benderdour M, Fahmi H.

Arthritis Res Ther. 2014 May 16;16(3):R113. doi: 10.1186/ar4564.

10.

LSD1 Histone Demethylase Assays and Inhibition.

Hayward D, Cole PA.

Methods Enzymol. 2016;573:261-78. doi: 10.1016/bs.mie.2016.01.020. Epub 2016 Feb 23. Review.

11.

Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells.

Han H, Yang X, Pandiyan K, Liang G.

PLoS One. 2013 Sep 6;8(9):e75136. doi: 10.1371/journal.pone.0075136. eCollection 2013.

12.

Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.

Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE.

Breast Cancer Res Treat. 2012 Feb;131(3):777-89. doi: 10.1007/s10549-011-1480-8. Epub 2011 Mar 31.

13.

3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.

Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L, Song Y.

J Med Chem. 2016 Jan 14;59(1):253-263. doi: 10.1021/acs.jmedchem.5b01361. Epub 2015 Dec 24.

14.

Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.

Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, Liu Y, Ward D, Quan J, Ye T, Zhang H.

Cancer Res. 2011 Dec 1;71(23):7238-49. doi: 10.1158/0008-5472.CAN-11-0896. Epub 2011 Oct 5.

15.

Identification of cell-active lysine specific demethylase 1-selective inhibitors.

Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N.

J Am Chem Soc. 2009 Dec 9;131(48):17536-7. doi: 10.1021/ja907055q.

PMID:
19950987
16.

Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.

Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y.

Carcinogenesis. 2013 Jun;34(6):1196-207. doi: 10.1093/carcin/bgt033. Epub 2013 Jan 25.

17.

Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.

Zhou C, Kang D, Xu Y, Zhang L, Zha X.

Chem Biol Drug Des. 2015 Jun;85(6):659-71. doi: 10.1111/cbdd.12461. Epub 2014 Dec 22.

PMID:
25346381
18.

Epigenetic regulation of Atrophin1 by lysine-specific demethylase 1 is required for cortical progenitor maintenance.

Zhang F, Xu D, Yuan L, Sun Y, Xu Z.

Nat Commun. 2014 Dec 18;5:5815. doi: 10.1038/ncomms6815.

19.

Histone H3 peptide based LSD1-selective inhibitors.

Kakizawa T, Ota Y, Itoh Y, Tsumoto H, Suzuki T.

Bioorg Med Chem Lett. 2015 May 1;25(9):1925-8. doi: 10.1016/j.bmcl.2015.03.030. Epub 2015 Mar 20.

PMID:
25827526
20.

Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.

Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schüle R, Buettner R.

Int J Cancer. 2012 Dec 1;131(11):2704-9. doi: 10.1002/ijc.27555. Epub 2012 Jun 28.

Supplemental Content

Support Center